Bradley Pharmaceuticals is hiring about 60 reps as it gearsup to launch Elestrin, a low-dose estrogen gel for treating the symptoms ofmenopause.
The reps will pitch Elestrin to OB/GYNs as part of Bradley’sKenwood Therapeutics division, which received FDA approval for the product lastDecember.
The company estimates the size of the US estrogen therapy market, whichconsists of oral and topical products, at $1.3 billion. The topical market is onlyworth about $300 million.
Bradley in-licensed Elestrin from BioSante Pharmaceuticals latelast year and has the exclusive USmarketing rights.
The small specialty firm says Elestrin fits into its strategicplan to in-license Phase II and Phase III drugs with long- term intellectualproperty protection and bring them to market. Elestrin’s patent protects ituntil 2022.
